The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Agendia; Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Eisai; Genomic Health; Gilead Sciences; GlaxoSmithKline; Immunomedics (Inst); Lilly; MSD Oncology; Myriad Genetics; Novartis; Pfizer; PharmaMar; Pierre Fabre; Roche/Genentech; Seagen; Tesaro
Consulting or Advisory Role - Amgen; AstraZeneca (Inst); CureVac; Eisai; Genomic Health; Gilead Sciences; GlaxoSmithKline; Immunomedics (Inst); Pfizer; Roche (Inst); Tesaro; Vaccibody (Inst)
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); MSD Oncology (Inst); Novartis; Roche/Genentech (Inst); Tesaro (Inst); Vaccibody (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
Biomarkers for response to immunotherapy in triple-negative breast cancer: Differences between survival and pCR biomarkers.
 
Carsten Denkert
Stock and Other Ownership Interests - Sividon Diagnostics
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Lilly; Merck; Molecular Health; MSD Oncology; Roche
Research Funding - Myriad Genetics (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Patent application WO2020109570A1 - cancer immunotherapy; Patent applications WO2015114146A1 and WO2010076322A1- therapy response; VMScope digital pathology software
 
Andreas Schneeweiss
Honoraria - Amgen; AstraZeneca/Daiichi Sankyo; Aurikamed; Bayer; Celgene; ClinSol; Connectmedica; Gilead Sciences; GlaxoSmithKline; I-MED; Lilly; MCI Deutschland; Metaplan; MSD; NanoString Technologies; Novartis; Onkowissen; Pfizer; Pierre Fabre; Promedicis; Roche; Seagen; Streamedup!; Tesaro; Teva; Thieme
Research Funding - Celgene (Inst); Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - Celgene; Pfizer; Roche
 
Julia Rey
No Relationships to Disclose
 
Thomas Karn
Patents, Royalties, Other Intellectual Property - Patent EP18209672 pending
 
Michael Braun
Consulting or Advisory Role - Exact Sciences; Novartis
Speakers' Bureau - Novartis
 
Jens Bodo Huober
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Eisai; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Hexal; Lilly; MSD; Novartis; Pfizer; Roche
Research Funding - Bristol-Myers Squibb (Inst); Hexal (Inst); Lilly (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Daiichi Sankyo; Novartis; Pfizer; Roche
 
Hans-Peter Sinn
No Relationships to Disclose
 
Dirk Michael Zahm
No Relationships to Disclose
 
Claus Hanusch
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis; Roche
 
Frederik Marmé
No Relationships to Disclose
 
Jenny Furlanetto
No Relationships to Disclose
 
Joerg Thomalla
No Relationships to Disclose
 
Jens U. Blohmer
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai Germany; Exact Sciences; Gilead Sciences; Lilly; Molecular Health; MSD Oncology; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Amgen; AstraZeneca; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Pfizer; Roche
 
Marion van Mackelenbergh
Honoraria - Amgen; AstraZeneca/Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Lilly; Molecular Health; Mylan; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - Amgen; AstraZeneca/Daiichi Sankyo; Genomic Health; Gilead Sciences; GlaxoSmithKline; Lilly; Molecular Health; Molecular Health; Mylan; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Travel, Accommodations, Expenses - Daiichi Sankyo Europe GmbH; Lilly
 
Peter Staib
Research Funding - Abbvie; Amgen; AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences; Janssen-Cilag; Novartis; Pfizer
 
Christian Jackisch
Honoraria - AstraZeneca; Exact Sciences; Lilly; Novartis; Pfizer; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Genomic Health; Genomic Health; Novartis; Roche; Tesaro
Research Funding - Genomic Health (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Novartis; Roche
 
Peter A. Fasching
Honoraria - Agendia; AstraZeneca; BionTech (Inst); Cepheid (Inst); Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst); Roche
 
Bruno Valentin Sinn
Patents, Royalties, Other Intellectual Property - Patent pending WO2017189976A1; Patent pending WO2020109570A1
 
Michael Untch
Honoraria - Agendia (Inst); Amgen (Inst); Art tempi (Inst); AstraZeneca (Inst); Daiji Sankyo (Inst); Eisai Europe (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Sanofi (Inst); Seagen (Inst)
Consulting or Advisory Role - Agendia (Inst); Amgen (Inst); Art tempi (Inst); AstraZeneca (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Molecular Health (Inst); MSD Oncology (Inst); Mylan (Inst); Myriad Genetics (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Sanofi Aventis GmbH (Inst)
 
Sibylle Loibl
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); EirGenix (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Medscape (Inst); Merck KGaA (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Puma Biotechnology (Inst); Roche (Inst); Seagen (Inst)
Speakers' Bureau - AstraZeneca (Inst); Daiichi Sankyo Europe GmbH (Inst); Medscape (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Samsung (Inst)
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Digital Ki67 Evaluator, VM Scope GmbH (Inst); Patent Issued EP15702464.7 (Inst); Patent Pending EP14153692.0 (Inst); Patent Pending EP19808852.8 (Inst); Patent Pending EP21152186.9 (Inst)